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Introduction
A growing number of network meta-analyses (NMAs) are being published in the medical literature (Zarin et al., 2017) . NMAs offer a way to make comparisons between many interventions simultaneously, helping to synthesize large amounts of data relating to clinical outcomes. NMAs can also make indirect comparisons between interventions that have not been compared in randomized controlled trials (RCTs) and rank interventions in terms of their relative efficacy or safety. While there are clear advantages to NMAs, their conduct and interpretation is more complex than that of pairwise meta-analyses. Therefore, it is important for those conducting and reading NMAs to learn how to understand and interpret the findings. In this article, we will: (1) delineate how NMAs differ from pairwise meta-analyses, (2) describe types of evidence in a NMA (3) explain NMA model assumptions, (4) provide readers with an approach to interpreting an NMA, (5) discuss areas of ongoing methodological research, and (6) provide a brief overview of how to conduct a systematic review and NMA. Two NMAs on treatments for psoriasis will be used to illustrate these concepts (Jabbar-Lopez et al., 2017 , Reich et al., 2012 ).
Comparing Pairwise and Network Meta-Analysis
Pairwise and network meta-analyses are compared and contrasted in Table 1 . Pairwise metaanalyses are applied when the desired endpoint is to derive a summary effect estimate across a number of studies that compare the same two interventions (Panel A, Figure 1 ) (Abuabara et al., 2012) . However, for many comparative effectiveness questions, the goal is to understand the relative efficacy and safety of more than two interventions. For example, therapeutic decision making for a patient with moderate to severe chronic plaque psoriasis requires comparison of all possible interventions, including adalimumab, etanercept, other biologics, traditional systemic Page 3 of 42 medications, and small molecule targeted agents. This can be accomplished with NMA, from which summary effect estimates can be derived across more than two interventions, some of which have never been directly compared. Like pairwise meta-analyses, NMAs can be conducted in a frequentist or Bayesian framework (Chaimani et al., 2013 , Dias et al., 2018 , van Valkenhoef and Kuiper, 2016 ).
Direct and Indirect Evidence
Estimates of relative efficacy or safety from NMA models can be derived by combining both direct and indirect evidence from intervention comparisons that form a connected network ( Figure 2 ) (see Assumptions of Network Meta-Analysis below). Direct evidence describes data taken from at least one RCT. Indirect evidence is derived from NMA models to describe the relative efficacy or safety for intervention comparisons that have not been studied in an RCT (Panel B, Figure 1 ). When a comparison is informed by both direct and indirect evidence, this is referred to as a mixed effect estimate (Dias et al., 2018) . For example, in the NMA conducted by Jabbar-Lopez et al., on the evaluation of biologic therapies for psoriasis, there was no RCT evidence directly comparing adalimumab and etanercept for the outcome of 'clear/nearly clear'; however, there were direct comparisons between (1) adalimumab and placebo and (2) 
Assumptions of Network Meta-Analysis
There are 4 key assumptions of NMAs: (a) network connectivity (b) homogeneity, (c) transitivity, and (d) consistency ( Table 2 ). The requirement for network connectivity is unique to Page 4 of 42 NMA. Interventions must be connected to the network to draw any conclusions about their direct and indirect relationships with other interventions. In Figure 2 , each intervention is connected to at least one other intervention in each network. If a treatment comparison is not connected to any other treatments in the network, it cannot be a part of the NMA.
Readers are likely familiar with the concept of homogeneity: the true intervention effect should be sufficiently similar across all studies making a direct comparison between the same two intervention groups. Similar to pairwise meta-analyses, different potential sources of heterogeneity must be considered in studies included in NMAs: clinical, methodological, and statistical. If heterogeneity is anticipated between studies, then a random-effects as opposed to fixed-effects model should be implemented (Higgins and Green) . Consistency is the statistical measure of transitivity. There may be inconsistency in a closed network loop if there is an imbalance of effect modifiers across treatment comparisons. In essence, direct and indirect effect estimates can be compared within a network to assess their Page 5 of 42 level of disagreement. There are tests that assess for consistency in a network as a whole (global tests) or at certain paths (e.g. closed loops) of a network (local tests) (Dias et al., 2018) . For example, the results of a loop-specific approach to the assessment of inconsistency (local test) are presented in Figure 4 . There is inconsistency in the closed loop containing three comparisons: placebo-methotrexate, placebo-infliximab, and methotrexate-infliximab. This means that the direct and indirect effect estimates of one of the treatment comparisons within this closed loop are significantly different from one another (the inconsistency factor's 95% confidence interval does not cross zero). There is no inconsistency identified in the other closed loops. It is possible that statistical tests of consistency may fail to identify inconsistency; therefore, it is important to consider whether the transitivity assumption has been met prior to undertaking a NMA.
RCTs in a NMA are subject to the same biases as those included in pairwise meta-analyses.
Critical appraisal of RCTS in a NMA is important because studies at high risk of bias can lead to violations of the homogeneity, transitivity and consistency assumptions. For example, if indirect evidence from a closed network loop of studies at low risk of bias in all aspects of critical appraisal did not show a significant benefit to receiving treatment, but one study (direct evidence), at high risk of bias from lack of participant and outcome assessor blinding, found a benefit to receiving treatment, this will violate the transitivity (and possibly the consistency) assumption. Similarly, between-study heterogeneity will be created if one study at high risk of bias due to lack of participant and outcome assessor blinding found a benefit to receiving a treatment, while a second study that was at low risk of bias on these aspects of critical appraisal did not find such a benefit. 
Interpreting a Network Meta-Analysis
A number of different measures of intervention efficacy and safety can be derived from NMAs (Table 3 ) (Dias et al., 2018) . Figures and explanations for network plots (Figure 2) , surface under the cumulative ranking (SUCRA) curves (Figure 3 ), an inconsistency plot (Figure 4) , and a comparison-adjusted funnel plot ( Figure 5 ) are provided (Jabbar-Lopez et al., 2017) . By convention, a higher mean rank or greater SUCRA value indicates that an intervention is either more efficacious or safer (Dias et al., 2018 (Reich et al., 2012) . In this case, the RR value represents the mean of the RR posterior distribution for each relative treatment effect, and the 95% CrI represents the range of values within which there is a 95% probability that the true value of the RR is found, given the observed data. In contrast, Jabbar-Lopez et al. used a frequentist NMA approach (Jabbar-Lopez et al., 2017) . In a frequentist framework, the 95% confidence interval means that there is a 95% chance of the true RR value being found within the intervals, given repeated randomized sampling. Frequentist modeling treats data as random and parameters as fixed unknown constants; whereas, Bayesian modeling treats data as fixed and parameters as random (Kadane, 1995) .
Knowledge users can use the International Society for Pharmacoeconomics and Outcomes
Research (ISPOR) tool for interpreting NMAs in health care decision-making or the Journal of the American Medical Association (JAMA) Users' Guide to the Medical Literature on NMAs for interpreting and critically appraising a systematic review and NMA (Jansen et al., 2014 , Mills et al., 2012 . The GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach has also been extended to assess the certainty of NMA results. It provides a framework for determining the quality of evidence in NMA-derived effect estimates for each outcome (Brignardello-Petersen et al., 2018 , Salanti et al., 2014 .
Areas of Ongoing Methodological Research in Network Meta-Analysis
There remain a number of questions about how to apply NMA methods in clinical and policy decision-making. For example, what is the best way to present NMA results to knowledge users?
In addition to reporting summary effect estimates, is it best to report all of the SUCRA curve values individually or should a method like a rank-heat plot be utilized (Veroniki et al., 2016b) ?
A rank-heat plot is a collated graphical representation of ranking statistics demonstrating the comparative effect of interventions on a number of outcomes ( Figure 6 ). How can data from nonrandomized studies be incorporated into NMAs? For adverse event data, in particular, this is an important topic because many RCTs are under-powered to detect the potential for harm. Several models have been proposed to include non-randomized studies in NMAs: (1) naïve pooling, (2) data from non-randomized studies as prior information, and (3) a three-level hierarchical model with an additional level of uncertainty to account for the inclusion of different study designs (Schmitz et al., 2013) . Lastly, how can individual patient-level data best be included in NMAs to account for potential effect modifiers? Meta-analysts are using several methods to incorporate individual patient-level data, including one-and two-stage Bayesian hierarchical NMA models (Veroniki et al., 2016a) .
Conducting a Systematic Review and Network Meta-Analysis
We provide an overview of the steps necessary to conduct a systematic review and network meta-analysis in Table 4 . There are statistical packages available to conduct frequentist and Bayesian NMAs (Chaimani et al., 2013, van Valkenhoef and Kuiper, 2016) . In conducting a Bayesian NMA, special consideration needs to be given to the choice of prior information for stochastic model parameters (Dias et al., 2018) . Reich et al. implemented vague prior distributions for study-specific baselines in their NMA of biologic treatments for moderate to severe psoriasis, but minimally informative and informative priors are also used in Bayesian NMAs (Dias et al., 2018 , Reich et al., 2012 .
Summary
Researchers may wish to undertake a systematic review and NMA because they can: make indirect comparisons between interventions that have not been previously compared in RCTs, compare the relative efficacy or safety of more than two interventions simultaneously, and rank interventions in terms of their relative efficacy or safety. Much work has been done to improve the reporting and interpretability of NMA results; however, researchers and knowledge users must be cautious when reading NMA results and carefully consider many of the same limitations that face pairwise meta-analyses including potential threats to the validity of meta-analytic findings from systematic biases.
Summary Points
Comparing Pairwise and Network Meta-Analysis Figure 2 )?
Transitivity (1) Is there an imbalance in effect modifiers among studies included in the network? (2) In theory, could any patient randomized in one study within a network have been randomized to any of the other studies in this same network?
Consistency
(1) Where possible to assess, are the direct and indirect effect estimates from closed loops in the network in agreement? 
Ranking Statistics
frequently presented as a mean/median rank, SUCRA value (or P-Score) or probability of being the best treatment an intervention with a higher treatment ranking, SUCRA value, or probability of being the best is more efficacious or more likely to cause harm Inconsistency Plot a plot reporting the inconsistency factors (absolute difference between direct and indirect effect estimates) for each comparison in a closed network loop (see Figure  4) an inconsistency factor with a confidence interval that does not include zero indicates that there is significant inconsistency between direct and indirect effect estimates
Comparison-Adjusted
Funnel Plot similar to a funnel plot in pairwise meta-analyses; however,
(1) the x-axis is the difference between each study-specific effect estimate and pooled effect estimate for each comparison and
(2) comparisons have been ordered in a meaningful way (e.g. asymmetry in the plot indicates publication bias/small-study effects chronological treatment order) (see Figure 5 ) *Abbreviations: odds ratio (OR), mean difference (MD), standardized mean difference (SMD), hazard ratio (HR), network meta-analysis (NMA), SUCRA (surface under the cumulative ranking curve) 8. Assess for small-study effects and publication bias by using a plot such as the comparison-adjusted funnel plot.
9. Present summary effect estimates for interventions and an estimate of heterogeneity. You can also present ranking statistics such as a mean rank and a SUCRA value for each intervention.
10. Follow the recommendations of the PRISMA extension statement for the reporting of NMAs when submitting your systematic review and NMA for publication (Hutton et al., 2015) . Surface under the cumulative ranking (SUCRA) curves of treatments evaluating the psoriasis area and severity index (PASI) 75 at 12/16 weeks (Jabbar-Lopez et al., 2017) . The cumulative probability that each treatment is ranked among the top n (e.g. 1, 2, …, 8) treatments (y-axis) is plotted against each possible rank (x-axis) for treatments in the network. Predictive probabilities incorporate the uncertainty in our network estimates from heterogeneity. Ixekizumab (IXE) has the highest SUCRA value (96.4%) and placebo (PBO) has the lowest SUCRA value (0%). 
Figure 6. Example of a Rank-Heat Plot
This is an example of a rank-heat plot of outcomes associated with insulin use in patients with type 1 diabetes mellitus. Each ring represents a different outcome. Outcomes are also specified in the legend. Each "slice" represents a different treatment. Treatments are ranked according to their surface under the cumulative ranking curve (SUCRA) values. Higher SUCRA values (in green) indicate more efficacious and safer treatments. Uncolored areas indicate that the treatment was not included in the NMA of that outcome. Abbreviations: hemoglobin A1c (A1c), twice daily (bid), once daily (OD), four times per day (qid).
Multiple Choice Questions
1. Which of the following are advantages of conducting a network meta-analysis as compared to a pairwise meta-analysis? a. make indirect comparisons between interventions that have not been previously compared in RCTs b. rank interventions in terms of their relative efficacy or safety c. increase the precision of our summary effect estimates by including both direct and indirect evidence d. all of the above 2. You read an article reporting the results of a systematic review and network meta-analysis.
The authors report there was no inconsistency detected in their network meta-analysis models. You should: a. accept the network meta-analysis results as robust because there was no inconsistency identified b. read further in the study methods and results section to see if the authors evaluated the transitivity assumption prior to conducting the network meta-analysis c. consider the similarities and differences between the studies included in the network meta-analysis to evaluate the transitivity assumption d. b and c 3. Which of the following model outputs are common to both pairwise and network metaanalysis? a. summary effect estimate (e.g. odds ratio, mean difference) b. mean rank c. surface under the cumulative ranking curve (SUCRA) value d. inconsistency plot 4. Which of the following scenarios best describes a homogeneous comparison? a. the mean age of patients enrolled in studies evaluating comparison AB is 65; whereas, the mean age of patients enrolled in studies evaluating comparison AC is 70 b. among three studies evaluating comparison AB, the mean age of patients enrolled in study #1 is 65, the mean age of patients enrolled in study #2 is 66, and the mean age of patients enrolled in study #3 is 63 c. the mean age of patients enrolled in studies evaluating comparison AB is 65; whereas, the mean age of patients enrolled in studies evaluating comparison AC is 66 d. among three studies evaluating comparison AB, the mean age of patients enrolled in study #1 is 65, the mean age of patients enrolled in study #2 is 45, and the mean age of patients enrolled in study #3 is 80 5. You conduct a network meta-analysis on the comparative risk of death from new drugs used to treat atopic dermatitis. 1. The correct answer is d. All of the listed choices are advantages of network meta-analysis over pairwise meta-analysis. 2. The correct answer is d. You should never rely solely on tests of inconsistency to detect inconsistency in a network meta-analysis. You must first conduct an assessment of transitivity across comparisons in the network to ensure effect modifiers are balanced. Authors should conduct an assessment of transitivity and they should provide a way for readers of their study to assess the transitivity assumption as well. 3 . The correct answer is a. Summary effect estimates are reported in both pairwise and network meta-analyses. 4 . The correct answer is b. The three studies that have compared treatments A and B have a similar distribution of patient ages, which indicates there is homogeneity with regards to patient age within this treatment comparison. Choice c is an example of the transitivity assumption. Patients enrolled in studies comparing treatments A and B and treatments A and C are similar in age, which confirms the transitivity assumption to be valid with regards to the potential effect modifier of patient age. 5. The correct answer is a. Drugs with a lower mean rank are associated with a higher risk of death. This is an example of a rank-heat plot of outcomes associated with insulin use in patients with type 1 diabetes mellitus. Each ring represents a different outcome. Outcomes are also specified in the legend. Each "slice" represents a different treatment. Treatments are ranked according to their surface under the cumulative ranking curve (SUCRA) values. Higher SUCRA values (in green) indicate more efficacious and safer treatments. Uncolored areas indicate that the treatment was not included in the NMA of that outcome.
Abbreviations: hemoglobin A1c (A1c), twice daily (bid), once daily (OD), four times per day (qid). All of the listed choices are advantages of network meta-analysis over pairwise meta-analysis.
Question 2:
You read an article reporting the results of a systematic review and network meta-analysis. The authors report there was no inconsistency detected in their network meta-analysis models. You should:
❍ accept the network meta-analysis results as robust because there was no inconsistency identified ❍ read further in the study methods and results section to see if the authors evaluated the transitivity assumption prior to conducting the network meta-analysis ❍ consider the similarities and differences between the studies included in the network meta-analysis to evaluate the transitivity assumption • b and c
